Drawing on Deal Experience to Develop Portolio Strategy
A biosimilars developer had five assets in development and needed to determine its investment and portfolio strategy. Proaltus performed a rigorous commercial and competitor landscape analysis and weighed these insights in the context of the deal market.
Working closely with the client’s business and technical teams, Proaltus elucidated a range of investment, financing, and partnering alternatives. Partnering and investment strategy recommendations for different portfolio alternatives included timing and execution considerations on a region by region and asset by asset basis. The recommendations were approved by the board and are being pursued in their entirety.
Pricing and Market Access Strategy:
Including Payer Perspectives to Support Commercial Success
A global pharmaceutical company had in-licensed two anti-infective compounds with outstanding pricing and reimbursement risks. The client wished to understand more clearly the trade-offs between different prices, clinical profiles, and access / reimbursement levels and the resulting revenue impacts.
Working with a cross-functional client team that included US and EU5 representation, Proaltus performed a thorough information gap analysis that included internal stakeholder interviews within the client organization, conducted qualitative interviews with physicians and payers, ran quantitative exercises with physicians and payers, and developed a robust revenue model. Recommendations included optimal pricing and related market access recommendations that considered the level of differentiation each product offered as well as royalty payments.
Innovative Licensing Concepts Deliver Strategic Value
MaxCyte, a cell therapy company, faced two strategic imperatives: generating near-term revenue and deriving value from its academic collaborations. Bringing a fresh perspective, a new path forward was identified: instead of advancing drug candidates through an extended regulatory path, at an earlier clinical stage MaxCyte successfully accelerated the out-licensing of a therapeutic program that had been previously in-licensed from an academic center.
“[Proaltus General Partner] Chris Lehman served as a critical catalyst in our strategic market launch session for a new therapeutic and led the implementation of our business development effort.” – Doug Doerfler, CEO, MaxCyte, Inc.